Patent applications published 26 October 2011
Selected patent applications from the weekly European Patents Bulletin
- Acne vulgaris treatment regimen
Guthery, Eugene B 2378872*
- Method of treating neuropathic pain
Zhang, Jie 2378873*
- Sporicidal hand sanitising lotion
Minnitech 2378874*
- Cell permeant peptide-based inhibitor of kinases
Purdue Research Foundation 2378875*
- Lower dosage strength imiquimod formulations and short dosing regimens for treating actinic keratosis
Graceway Pharmaceuticals 2378876*
- Imidazolinone derivatives as CGRP receptor antagonists
Merck Sharp & Dohme 2378877*
- Inhibitors of diacylglycerol acyltransferase
Via Pharmaceuticals 2378878*
- Triazole derivatives for the treatment of Alzheimer’s disease
Merck Sharp & Dohme 2378879*
- Zeleplon gastroretentive drug delivery system
Intec Pharma 2378883*
- Use of cationic surfactants as acaricidal agents
Laboratorios Miret 2378884*
- 3.3.0 bicyclic GLYT1 inhibitors and methods of making and using same
Vanderbilt University 2378885*
- Polymorphs of (S)-3-aminomethyl-7-(3-hydroxy-propoxy)-3H-benzo[C] [1,2] oxaborol-1-ol
Anacor Pharmaceuticals; GlaxoSmithKline 2378886*
- Combined disinfectant and decontamination agent having increased effectivity
Bode Chemie; multiBIND biotec 2378887*
- Bacterial extract elicitor
Uniäo Brasiliara De Ecuador E Assistencia - Mantenedoro De Pucrs 2378888*
- Prophylactic/therapeutic agent for cancer
Takeda Pharmaceutical 2379053*
- Formulation for delivering lipid-lowering drugs by oral transmucosal administration
Perovitch, Philippe; Maury, Narc 2379054*
- Method of making sustained release microparticles
Oakwood Laboratories 2379055*
- Solid pharmaceutical compsn comprising at least one stabilising agent
KRKA 2379056*
- Phenylephrine formulations with improved stability
Novartis 2379057*
- Retigabine tablets, preferably having modified release
Ratiopharm 2379058*
- Controlled releasing compsn
Anhui Zhrongen Technology 2379059*
- Extended-release pharmaceutical formulations
aardvark Services 2379060*
- Precompacted fast-disintegrating formulations of compounds with a low oral bioavailability
Abbott Healthcare Products 2379061*
- Pharmaceutical product comprising one or more fumaric acid esters
Forward Pharma 2379062*
- Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
Forward Pharma 2379063*
- Long circulating nanoparticles for sustained release of therapeutic agents
Bind Biosciences 2379064*
- Capecitabine rapidly disintegrating tablets
F Hoffmann-La Roche 2379065*
- Use of opioid antagonists for the preparation of a medicament in the treatment of retinal degenerative diseases
Ak Kimya Ithalat-ihracat Ve Snayii Anonim Sirketi 2379066*
- Dosage regimen for a S1P receptor agonist
Novartis 2379067*
- Compounds effective against cancer
Schmidt-Wolf, Ingo 2379068*
- Dosage regimen of an S1P receptor agonist
Novartis 2379069*
- Stable water-based topical pharmaceutical creams and methods of making and using same
Imi International Medical Innovations (b/b/a Procris Pharmaceuticals) 2379070*
- Novel aliphatically substituted pyrazolopyridines, and the use thereof
Bayer Pharma AG 2379071*
- Reducing cholesterol levels with combined use of querceting and statin
Quercegen Pharmaceuticals 2379072*
- Methods of treating or preventing cancer and neurodegenerative diseases
Sloan Kettering Institute for Cancer Research 2379073*
- Macrolactine derivatives, method for the production thereof and use thereof for the treatment of cancer
Sanofi 2379074*
- Triazole derivatives for treatment of Alzheimer’s disease
Merck Sharp & Dohme 2379075*
- Phosphodiesterase inhibitors and uses thereof
The Trustees of Columbia University in the City of New York 2379076*
- Pharmaceutical compsn
Sun Pharma Advanced Research Company 2379077*
- Topical formulations of FLAP inhibitors for administration to an eye
Amira Pharmaceutical 2379078*
- Pharmaceutical formulations comprising voriconazole and processes for preparation thereof
Nanjing Cavendish Bio-Engineering Technology; Xu, Yongxiang 2379079*
- Pirenzepine as otoprotective agent
ProteoSys 2379080*
- Treatment of diarrhoea
Royal College of Surgeons in Ireland 2379081*
- Acne treatment powder foundation
Harmony Laboratories 2379082*
- Extended dicer substrate agents and methods for the specific inhibition of gene expression
Dicema Pharmaceuticals 2379083*
- Modulation of Factor 11 expression
Isis Pharmaceuticals 2379084*
- Pharmaceutical preparation comprising supernatant of blood mononuclear cell culture
Aposcience 2379085*
- Pharmaceutical preparation
Aposcience 2379086*
- Umbilical cord tissue derived cells for treating neuropathic pain and spasticity
Advanced Technology and Regenerative Medicine 2379087*
- Treatment of lung and pulmonary diseases and disorders
Advanced Technologies and Regenerative Medicine 2379088*
- Regeneration and repair of neural tissue following injury
Advanced Technologies and Regenerative Medicine 2379089*
- Compsns and methods for improved oral health
Nestec 2379091*
- Compsns comprising a lipophilic extract of Zingiber officinale and an extract of Cynara scolymus, which are useful for the prevention and treatment of oesophageal reflux and irritable bowel syndrome
Indena 2379092*
- Compsns for the treatment of gastro-oesophageal reflux disease (GERD)
Bionap 2379093*
- Polysaccharide from the goji berry fruit for kidneys and pancreas
Schrezenmeir, Jürgen 2379094*
- Compsns comprising lipophilic extracts of Zingiber officinale and Echinacea angustifolia for the prevention and treatment of gastro-oesophageal reflux and chemotherapy-induced emesis
Indena 2379095*
- TFPI inhibitors and methods of use
Baxter International; Baxter Healthcare; 3b Pharmaceuticals; Cosmix Molecular Biologicals 2379096*
- Compsns and methods to prevent cancer with cupredoxins
CDG Therapeutics 2379097*
- Compsns and methods to prevent cancer with cupredoxins
CDG Therapeutics 2379098*
- Method for the prophylaxis or treatment of flushing
Maatschap Interne Geneeskunde Rijnstate 2379099*
- Method of treating hyperglycaemia with GLP-1
Mannkind 2379100*
- Mutated antithrombins, a process for preparing the same, and their use as drugs
Université Paris-Sud XI; Assistance Publique-Hopitaux de Paris; Université Paris Descartes 2379101*
- FIBCD1 for the prevention and treatment of diseases
Syddansk Universiteit 2379102*
- Immunogenic compsn and use thereof
Isis Innovation 2379103*
- Injectable botulinum toxin formulations
Revance Therapeutics 2379104*
- Vaccine
The Secretary of State for Defence, DSTL Porton Down 2379105*
- Chlamydia antigens and uses thereof
Genocea Biosciences 2379106*
- Ljungan virus with improved replication characteristics
Apodemus 2379107*
- Immunoglobulin purification
F Hoffmann-La Roche 2379108*
- Combination of photodynamic therapy and anti-VEGF agents in the treatment of unwanted choroidal neovasculature
Qlt 2379109*
- Formulation for the buccal transmucosal administration of setrons
Perovitch, Phillippe; Maury, Marc 2379110*
- Narcotic drug formulations with deceased abuse potential
Paladin Labs 2379111*